ReviewFrontiers in immunology2026
TGF-β in chronic kidney disease: a controversy for decades.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is characterized by persistent inflammation, maladaptive repair and progressive renal fibrosis, yet therapeutic strategies capable of effectively targeting these interconnected processes remain limited. Transforming growth factor-β1 (TGF-β1) is a central mediator of renal fibrosis but also exerts essential immunoregulatory and tissue-protective functions, creating a fundamental therapeutic paradox. Emerging evidence indicates that these divergent effects are determined not simply by TGF-β1 abundance, but by its cellular source and target, spatial and temporal context, interactions with other signaling pathways, and the transcriptional cofactors that determine downstream gene expression. This context dependence may partly explain why systemic TGF-β neutralization has shown limited clinical efficacy despite compelling preclinical evidence. In this Review, we discuss the cell-specific and stage-dependent functions of TGF-β1 in CKD, controversies surrounding the cellular origins of renal myofibroblasts, and the integration of TGF-β signaling with some signaling pathways. We further examine lessons from clinical trials and emerging therapeutic approaches designed to selectively modulate pathological TGF-β signaling, including regulation of latent TGF-β activation, receptor and Smad signaling, transcriptional cofactors, tissue-targeted delivery, and gene- and cell-based strategies. Particular attention is given to transcriptional partner selection as a mechanism of signal reprogramming. The β-catenin-TCF/FOXO1 axis provides a proof of concept whereby redirecting β-catenin from profibrotic TCF-dependent transcription toward FOXO1-associated anti-inflammatory and reparative programs may preserve beneficial TGF-β functions while limiting fibrosis. We propose that future TGF-β-targeted therapy should move beyond global pathway inhibition toward spatially, temporally and molecularly informed signal reprogramming, supported by biomarker-guided patient stratification and emerging single-cell and spatial technologies. Such precision modulation may provide a more rational strategy to suppress pathological fibrosis while preserving immune homeostasis and regenerative capacity in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.